- Hypertrophic Cardiomyopathy (HCM)
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
CIGNA Acquires UK Foothold
Cigna will acquire FirstAssist Insurance Services, a travel and protection insurance company based in the United Kingdom, from Barclays Private Equity. The acquisition will add a new product line to Cigna's global portfolio, enabling the company to expand its individual business.
Cigna will acquire FirstAssist Insurance Services, a travel and protection insurance company based in the United Kingdom, from Barclays Private Equity. The acquisition will add a new product line to Cigna's global portfolio, enabling the company to expand its individual business. Pending regulatory approval, the acquisition is expected to close this year.
“Cigna is continually seeking opportunities to grow our business around the world - it's part of our ‘Go Deep. Go Global. Go Individual.’ strategy,” says William L. Atwell, president of Cigna International.
FirstAssist, which has 480 employees, has nearly 3 million policyholders in the UK. According to Cigna, travel in major European and Asian markets is up an average of 8% in 2010, which presents an opportunity to expand the business on a worldwide scale.
In addition to expansion into the UK, Atwell says FirstAssist brings an expanded product range that is new to Cigna's portfolio and can be offered to partners and customers in Europe and Asia, as well as doubling the number of Cigna’s affinity partners. FirstAssist maintains relationships with about 150 local, pan-European and multinational affinity partners.
Go back to the Managed Healthcare Executive eNews newsletter.
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
35th World AIDS Day Marks 20 Years of PEPFAR: Challenges and Strategies to Combat HIV/AIDS
November 29th 2023PEPFAR, having invested $100 billion and saved 25 million lives in the global fight against HIV/AIDS, faces Congressional hurdles in its reauthorization due to abortion debates. Despite widespread support and no evidence of abortion-related activities, the legislative process is at a standstill. Members of PEPFAR and authors of a recent editorial stress the significance of PEPFAR and advocate for integrating behavioral and social science into healthcare programs to achieve UNAIDS targets and address barriers in HIV/AIDS testing and treatment.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen
Study Raises Concerns Over Insurance Barriers to HIV Prevention Medications
November 29th 2023Despite its efficacy, PrEP remains underutilized compared to the need for it. High costs are among the barriers to PrEP use, along with limited knowledge among clinicians, lack of health insurance, stigma, and underestimation of personal HIV risk.
Read More
